Author:
Chow Laura Q. M.,Gustafson Daniel L.,O’Bryant Cindy L.,Gore Lia,Basche Michele,Holden Scott N.,Morrow Mark C.,Grolnic Stacy,Creese Brian R.,Roberts Kaye L.,Davis Kat,Addison Russell,Eckhardt S. Gail
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Reference55 articles.
1. Amiral J, Bridey F, Dreyfus M, Vissoc AM, Fressinaud E, Wolf M, Meyer D (1992) Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost 68:95–96
2. Anderson RL, Lelekakis M, Lowen D et al (1998) Inhibition of lung metastasis from a breast carcinoma using PI88, a heparanase inhibitor. (abstr). Proc Metastatic Res Soc
3. Baker SD, Zhao M, Lee CK, Verweij J, Zabelina Y, Brahmer JR, Wolff AC, Sparreboom A, Carducci MA (2004) Comparative pharmacokinetics of weekly and every-three-weeks docetaxel. Clin Cancer Res 10:1976–1983
4. Bareschino MA, Morgillo F, Ciardiello F (2007) Combination of standard chemotherapy and targeted agents. J Thorac Oncol 2:S19–S23
5. Basche M, Gustafson DL, Holden SN, O’Bryant CL, Gore L, Witta S, Schultz MK, Morrow M, Levin A, Creese BR, Kangas M, Roberts K, Nguyen T, Davis K, Addison RS, Moore JC, Eckhardt SG (2006) A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors. Clin Cancer Res 12:5471–5480
Cited by
19 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献